Literature DB >> 35747422

CV complications of anti-cancer ICI therapy and their combinations: are we ready for challenges ahead?

Alexandros Georgiou1, Nadia Yousaf2.   

Abstract

Entities:  

Keywords:  cancer; cardiotoxicity; immune checkpoint inhibitors; myocarditis

Year:  2020        PMID： 35747422      PMCID： PMC9205254          DOI： 10.5837/bjc.2020.001

Source DB:  PubMed          Journal:  Br J Cardiol        ISSN： 0969-6113


× No keyword cloud information.
  21 in total

1.  Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.

Authors:  Khashayar Esfahani; Najwa Buhlaiga; Paméla Thébault; Réjean Lapointe; Nathalie A Johnson; Wilson H Miller
Journal:  N Engl J Med       Date:  2019-06-13       Impact factor: 91.245

2.  Factors Associated With Immune Checkpoint Inhibitor-Related Myocarditis.

Authors:  Yoshito Zamami; Takahiro Niimura; Naoto Okada; Toshihiro Koyama; Keijo Fukushima; Yuki Izawa-Ishizawa; Keisuke Ishizawa
Journal:  JAMA Oncol       Date:  2019-11-01       Impact factor: 31.777

Review 3.  Immune checkpoint inhibitors and cardiovascular toxicity.

Authors:  Alexander R Lyon; Nadia Yousaf; Nicolò M L Battisti; Javid Moslehi; James Larkin
Journal:  Lancet Oncol       Date:  2018-09       Impact factor: 41.316

Review 4.  Cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Jiun-Ruey Hu; Roberta Florido; Evan J Lipson; Jarushka Naidoo; Reza Ardehali; Carlo G Tocchetti; Alexander R Lyon; Robert F Padera; Douglas B Johnson; Javid Moslehi
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

5.  Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases.

Authors:  Suheil Albert Atallah-Yunes; Anis John Kadado; Gregory P Kaufman; Jaime Hernandez-Montfort
Journal:  J Cancer Res Clin Oncol       Date:  2019-04-26       Impact factor: 4.553

6.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

7.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

Authors:  Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

8.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Authors:  Troy Z Horvat; Nelly G Adel; Thu-Oanh Dang; Parisa Momtaz; Michael A Postow; Margaret K Callahan; Richard D Carvajal; Mark A Dickson; Sandra P D'Angelo; Kaitlin M Woo; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

9.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Authors:  Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

10.  Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

Authors:  Yucai Wang; Shouhao Zhou; Fang Yang; Xinyue Qi; Xin Wang; Xiaoxiang Guan; Chan Shen; Narjust Duma; Jesus Vera Aguilera; Ashish Chintakuntlawar; Katharine A Price; Julian R Molina; Lance C Pagliaro; Thorvardur R Halfdanarson; Axel Grothey; Svetomir N Markovic; Grzegorz S Nowakowski; Stephen M Ansell; Michael L Wang
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.